Prognostic Significance of Hormonal Markers of Recurrent Pregnancy Loss in Women With Hyperprolactinemia

Mukhammedaminova Diyora Timurovna; Mirzaeva Umida Zakhidovna; Maksudova Dilafruzkhon Ravshanovna; Begmatov Boburmirzo Bakhrom ugli

Authors

Mukhammedaminova Diyora Timurovna Tashkent State Medical University, assistant
Mirzaeva Umida Zakhidovna Tashkent State Medical University, Candidate of Medical Sciences, Assistant
Maksudova Dilafruzkhon Ravshanovna Assistant of Tashkent State Medical University
Begmatov Boburmirzo Bakhrom ugli Tashkent State Medical University, assistant

Keywords:

Hyperprolactinemia, habitual miscarriage, inhibin A, activin, HCG, hormonal markers, pregnancy prognosis

Abstract

This study is aimed at assessing the levels of fertility indicators (inhibin A, activin and chorionic gonadotropin - HCG) and their dynamic changes during pregnancy in women with hyperprolactinemia, as well as determining their prognostic significance in the development of habitual miscarriage in the first trimester. The study was conducted by a prospective comparative method, in which 93 pregnant women participated: 73 with hyperprolactinemia and habitual miscarriage, and 20 - healthy pregnant women. During the study, the levels of activin, inhibin A, HCG, and prolactin were studied throughout the trimester, and the results were statistically processed using the χ2 test, ANOVA, and ROC analysis methods. The results showed that in women with hyperprolactinemia, the hormonal profile is significantly disrupted in the early stages of pregnancy: the level of activin increases, inhibin A decreases, and the HCG level is significantly lower than in the control group. According to the results of ROC analysis, HCG has the highest prognostic value (AUC = 0.873; sensitivity - 93.2%), inhibin A is moderate, and activin has low diagnostic value.

References

Z. K. Abdulkadyrova and E. I. Abashova, “Inhibin as a reproductive biomarker. Part 1,” Journal of Obstetrics and Women’s Diseases, vol. 68, no. 3, pp. 61–70, 2019, doi: 10.17816/JOWD68361-70.

Z. K. Abdulkadyrova, M. I. Yarmolinskaya, A. M. Gzgzyan, et al., “Inhibin as a reproductive biomarker. Part 2,” Journal of Obstetrics and Women’s Diseases, vol. 68, no. 5, pp. 91–106, 2019, doi: 10.17816/JOWD68591-106.

V. Bernard, J. Young, and N. Binart, “Prolactin: A pleiotropic factor in health and disease,” Nature Reviews Endocrinology, vol. 15, no. 6, pp. 356–365, 2019, doi: 10.1038/s41574-019-0194-6.

M. R. Chester, A. Tirlapur, and K. Jayaprakasan, “Current management of recurrent pregnancy loss,” Obstetrics and Gynecology, vol. 24, pp. 260–271, 2022, doi: 10.1111/tog.12832.

L. K. Dzeranova, N. S. Bykanova, and E. A. Pigarova, “Hyperprolactinemia and pregnancy: Main achievements and unresolved issues,” Bulletin of Reproductive Health, no. 1, pp. 16–21, 2011.

European Society of Human Reproduction and Embryology (ESHRE), Recurrent Pregnancy Loss: Guideline, 2017.

D. R. Grattan and I. C. Kokay, “Prolactin: A pleiotropic neuroendocrine hormone,” Journal of Neuroendocrinology, vol. 20, no. 6, pp. 752–763, 2008, doi: 10.1111/j.1365-2826.2008.01736.x.

E. Hauzman, A. Murber, P. Fancsovits, et al., “Biochemical markers for IVF pregnancy outcome prediction,” Orvosi Hetilap, vol. 147, no. 30, pp. 1409–1420, 2006.

R. L. Jones, L. A. Salamonsen, H. O. Critchley, et al., “Inhibin and activin subunits in endometrium during cycle and early pregnancy,” Molecular Human Reproduction, vol. 6, no. 12, pp. 1107–1117, 2000, doi: 10.1093/molehr/6.12.1107.

A. A. Larina, O. V. Grigoryan, E. N. Andreeva, and L. K. Dzeranova, “Hyperprolactinemia and pregnancy,” Problems of Reproduction, no. 3, pp. 13–17, 2013.

H. Majeeed, A. Højgaard, P. Johannesen, et al., “Predictive value of serum hCG ratio, progesterone and inhibin A in early pregnancies,” European Journal of Obstetrics & Gynecology and Reproductive Biology, vol. 165, no. 1, pp. 66–69, 2012, doi: 10.1016/j.ejogrb.2012.07.020.

A. Majumdar and N. S. Mangal, “Hyperprolactinemia,” Journal of Human Reproductive Sciences, vol. 6, no. 3, pp. 168–175, 2013.

S. Muttukrishna, L. George, P. A. Fowler, et al., “Measurement of serum inhibin-A during human pregnancy,” Clinical Endocrinology, vol. 42, no. 4, pp. 391–397, 1995, doi: 10.1111/j.1365-2265.1995.tb02648.x.

M. Namwanje and C. W. Brown, “Activins and inhibins: Roles in development, physiology and disease,” Cold Spring Harbor Perspectives in Biology, vol. 8, no. 7, a021881, 2016, doi: 10.1101/cshperspect.a021881.

A. A. Olina, “Non-developing pregnancy and hyperprolactinemia,” RMJ Mother and Child, vol. 3, no. 2, pp. 64–69, 2020.

Practice Committee of the American Society for Reproductive Medicine, “Evaluation and treatment of recurrent pregnancy loss: A committee opinion,” Fertility and Sterility, vol. 98, pp. 1103–1111, 2012.

Royal College of Obstetricians and Gynaecologists, The Investigation and Treatment of Couples with Recurrent Miscarriage, Green-top Guideline No. 17, 2011.

S. Segal, H. Gor, N. Correa, et al., “Inhibin A as a marker for diagnosis of ectopic and early abnormal pregnancies,” Reproductive Biomedicine Online, vol. 17, no. 6, pp. 789–794, 2008, doi: 10.1016/S1472-6483(10)60406-3.

T. V. Sebko, L. A. Kheydar, and S. S. Koneeva, “Hyperprolactinemia,” Russian Medical Journal, vol. 22, no. 5, pp. 250–259, 2016.

E. A. Sosnova, “Hyperprolactinemic syndrome,” Archive of Obstetrics and Gynecology, vol. 4, no. 1, pp. 4–14, 2017, doi: 10.18821/2313-8726-2017-4-1-4-14.

A. Turasheva, G. Aimagambetova, T. Ukybassova, et al., “Recurrent pregnancy loss: etiology, risk factors, diagnosis and management,” Journal of Clinical Medicine, vol. 12, no. 12, p. 4074, 2023, doi: 10.3390/jcm12124074.

S. Thapa and K. Bhusal, Hyperprolactinemia. StatPearls Publishing, 2024.

R. Wijayarathna and D. M. de Kretser, “Activins in reproductive biology and beyond,” Human Reproduction Update, vol. 22, no. 3, pp. 342–357, 2016, doi: 10.1093/humupd/dmv058.